Dolasetron Mesylate Injection
» Dolasetron Mesylate Injection is a sterile solution, suitable for intravenous administration, containing Dolasetron Mesylate in a buffer solution. It contains not less than 90.0 percent and not more than 110.0 percent of the labeled amount of dolasetron mesylate (C19H20N2O3·CH4O3S·H2O).
Packaging and storage— Preserve in a single-dose container, protected from light. Store at controlled room temperature.
Labeling— Label it to indicate that it may be diluted with a suitable parenteral vehicle prior to intravenous infusion.
Identification, Infrared Absorption 197K
Test specimen— Transfer a portion of Injection, equivalent to about 100 mg of dolasetron mesylate, to a 150-mL beaker. Add about 20 mL of water and 10 mL of a sodium hydroxide solution (1 in 10). Mix, and allow to stand at room temperature for 30 minutes. Pass through a filtering crucible with fritted disk having a medium porosity, using about 100 mL of water to aid in the transfer. Dry the precipitate in a vacuum oven at 105 for 4 hours. Prepare a 1.5% mixture of the dried powder with potassium bromide.
Bacterial endotoxins 85 It contains not more than 2.7 USP Endotoxin Units per mg of dolasetron mesylate.
pH 791: between 3.2 and 3.8.
Particulate matter 788: meets the requirements for small-volume injections.
Other requirements— It meets the requirements under Injections 1.
Mobile phase— Proceed as directed in the Assay under Dolasetron Mesylate.
System suitability preparation— Dissolve accurately weighed quantities of USP Dolasetron Mesylate RS and indole-3-carboxylic acid in Mobile phase, and dilute quantitatively, and stepwise if necessary, with Mobile phase to obtain a solution having known concentrations of about 0.1 mg per mL and 0.02 mg per mL, respectively.
Standard preparation— Dissolve an accurately weighed quantity of USP Dolasetron Mesylate RS in Mobile phase to obtain a solution having a known concentration of about 0.1 mg per mL.
Assay preparation— Using a “to contain” pipet, transfer 2.5 mL of Injection to a 50-mL volumetric flask. Rinse the pipet with several portions of Mobile phase, and collect the rinses in the same flask. Dilute with Mobile phase to volume, and mix. Pipet 5.0 mL of this solution into a 50-mL volumetric flask, dilute with Mobile phase to volume, and mix.
Chromatographic system (see Chromatography 621)— Prepare as directed in the Assay under Dolasetron Mesylate. Chromatograph the System suitability preparation, and record the peak responses as directed for Procedure: the resolution, R, between indole-3-carboxylic acid and dolasetron mesylate is not less than 4; and the tailing factor for the dolasetron mesylate peak is not more than 1.8. Chromatograph the Standard preparation, and record the peak responses as directed for Procedure: the relative standard deviation for replicate injections is not more than 1.5%.
Procedure— Separately inject equal volumes (about 20 µL) of the Standard preparation and the Assay preparation into the chromatograph, record the chromatograms, and measure the areas for the major peaks. Calculate the quantity, in mg, of dolasetron mesylate (C19H20N2O3·CH4O3S·H2O) in each mL of Injection taken by the formula:
200C(rU / rS)
in which C is the concentration, in mg per mL, of USP Dolasetron Mesylate RS in the Standard preparation; and rU and rS are the peak responses obtained from the Assay preparation and the Standard preparation, respectively.
Auxiliary Information— Please check for your question in the FAQs before contacting USP.
Topic/Question Contact Expert Committee
Monograph Elena Gonikberg, Ph.D.
Senior Scientist
(MDGRE05) Monograph Development-Gastrointestinal Renal and Endocrine
Reference Standards Lili Wang, Technical Services Scientist
85 Radhakrishna S Tirumalai, Ph.D.
Senior Scientist
(MSA05) Microbiology and Sterility Assurance
USP32–NF27 Page 2198
Pharmacopeial Forum: Volume No. 29(1) Page 60
Chromatographic Column—
Chromatographic columns text is not derived from, and not part of, USP 32 or NF 27.